Safety and Efficacy of Dasatinib Treatment Change for Patients Previosly Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study
Valentín García‐Gutiérrez(Universidad de Alcalá), Juan Luis Steegmann(Hospital Universitario de La Princesa), Isabel Montero(Hospital Universitario Virgen del Rocío), Fermín Sánchez‐Guijo(Universidad de Salamanca), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Rosa Ayala(Hospital Universitario 12 De Octubre), César Soto(Povisa Hospital), Raquel de Paz(Hospital Universitario La Paz), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Felipe Casado(Hospital Virgen de la Salud), Concepción Boqué(Institut Català d'Oncologia)
Cited by 1
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523